BioVector® SF8628 人类弥漫性中线胶质瘤 (H3.3-K27M) 细胞系 / SF8628 Human Diffuse Midline Glioma (H3.3-K27M) Cell Line

通用定义 / General Definition:BioVector® SF8628 (H3.3-K27M) 是一种源自儿科弥漫性中线胶质瘤（DMG，原称 DIPG）的肿瘤细胞系。该细胞系的核心特征是在 H3F3A 基因中携带典型的 K27M 突变。这一突变导致组蛋白 H3.3 的第 27 位赖氨酸被甲硫氨酸取代，进而抑制 Polycomb 抑制复合物 2 (PRC2) 的活性，造成全基因组范围内 H3K27me3（三甲基化）水平的大幅下降。它是目前全球范围内研究儿童高恶性胶质瘤、表观遗传学调控及临床前药物筛选的关键生物学模型。

BioVector® SF8628 (H3.3-K27M) is a tumor cell line derived from a pediatric patient with Diffuse Midline Glioma (DMG, formerly known as DIPG). The core characteristic of this cell line is the hallmark K27M mutation in the H3F3A gene. This mutation results in the substitution of lysine 27 with methionine in histone H3.3, which inhibits the activity of the Polycomb Repressive Complex 2 (PRC2) and causes a global reduction in H3K27me3 (trimethylation) levels. It is a pivotal biological model globally for studying pediatric high-grade gliomas, epigenetic regulation, and preclinical drug screening.

BioVector® SF8628 (H3.3-K27M) 技术说明书 (Technical Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® SF8628 (H3.3-K27M) 人 DIPG/DMG 细胞

• 突变信息： H3.3 K27M (H3F3A 突变)

• 生长特性： 贴壁生长（可适应悬浮神经球培养）

• 细胞形态： 成纤维细胞样或纺锤形

2. 培养条件

• 基础培养基： BioVector® DMEM 培养基 或 DMEM/F12 (1:1)

• 血清添加： 10% BioVector® 优质胎牛血清 (FBS)

• 培养环境： 37 摄氏度，5% CO2，饱和湿度

• 传代比例： 1:3 至 1:6，建议在 80% 到 90% 汇合度时传代

3. 细胞应用

• 表观遗传机制： 研究 H3K27M 突变如何通过重塑染色质结构驱动肿瘤发生。

• 药物评价： 筛选针对组蛋白修饰酶（如 HDAC、EZH2）的新型抑制剂。

• 生物标志物发现： 探索 DIPG 进展中的新型分子靶点。

4. 注意事项

• 突变验证： H3.3-K27M 突变是其核心特征，建议定期通过蛋白印迹 (Western Blot) 检测 K27M 蛋白表达情况。

• 细胞干性： 若需研究胶质瘤干细胞特性，建议使用 BioVector® 无血清神经干细胞培养基进行诱导。

English Datasheet

1. General Product Information

• Product Name: BioVector® SF8628 (H3.3-K27M) Human DIPG/DMG Cell Line

• Mutation Status: H3.3 K27M (H3F3A mutation)

• Growth Properties: Adherent (adaptable to neurosphere suspension culture)

• Morphology: Fibroblast-like or spindle-shaped

2. Culture Conditions

• Basal Medium: BioVector® DMEM Medium or DMEM/F12 (1:1)

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Incubation: 37 degrees Celsius, 5% CO2, Saturated Humidity

• Subculturing: 1:3 to 1:6 ratio; recommended at 80% to 90% confluence

3. Applications

• Epigenetic Mechanisms: Investigating how the H3K27M mutation drives tumorigenesis by reshaping chromatin structure.

• Drug Evaluation: Screening novel inhibitors targeting histone-modifying enzymes (e.g., HDAC, EZH2).

• Biomarker Discovery: Exploring new molecular targets in the progression of DIPG.

4. Key Usage Notes

• Mutation Stability: Since H3.3-K27M is the hallmark, periodically verify the K27M protein expression via Western Blotting or DNA sequencing.

• Stemness Maintenance: To study glioma stem cell (GSC) properties, transition the cells into BioVector® serum-free neural stem cell media (supplemented with B27, EGF, and bFGF).

Note: Handle BioVector® SF8628 (H3.3-K27M) cells under Biosafety Level 2 (BSL-2) protocols. To maintain the consistent epigenetic profile of this line, the use of BioVector® validated media and high-grade fetal bovine serum is highly recommended.

Supplier生产厂家: BioVector NTCC典型培养物保藏中心

E-mail: BioVector@163.com

http://www.biovector.net